[{"id":"076cd6de-9c13-4f66-953e-ae61920d0ae1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05911217","created_at":"2023-06-20T14:07:52.799Z","updated_at":"2024-07-02T16:35:00.806Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer","source_id_and_acronym":"NCT05911217","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e satricabtagene autoleucel (CT041)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-27"},{"id":"5d0bb067-65b0-4094-b54b-a91e3fcb9734","acronym":"CT041-CG4006","url":"https://clinicaltrials.gov/study/NCT03874897","created_at":"2021-03-09T08:59:23.397Z","updated_at":"2024-07-02T16:35:06.986Z","phase":"Phase 1","brief_title":"Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.","source_id_and_acronym":"NCT03874897 - CT041-CG4006","lead_sponsor":"Peking University","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • cyclophosphamide • satricabtagene autoleucel (CT041)"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 03/26/2019","start_date":" 03/26/2019","primary_txt":" Primary completion: 03/20/2021","primary_completion_date":" 03/20/2021","study_txt":" Completion: 01/26/2024","study_completion_date":" 01/26/2024","last_update_posted":"2024-04-30"},{"id":"6d1b5764-e77a-48d0-bb8b-8c63cc77a81d","acronym":"LB1908-1001","url":"https://clinicaltrials.gov/study/NCT05539430","created_at":"2022-09-14T18:56:15.361Z","updated_at":"2024-07-02T16:35:15.456Z","phase":"Phase 1","brief_title":"Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT05539430 - LB1908-1001","lead_sponsor":"Legend Biotech USA Inc","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LB1908"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-11"},{"id":"8cbaeb2f-65c4-4a58-98fe-a12c3fec7f28","acronym":"","url":"https://clinicaltrials.gov/study/NCT05472857","created_at":"2022-07-25T20:54:35.084Z","updated_at":"2024-07-02T16:35:16.126Z","phase":"Phase 1","brief_title":"Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression","source_id_and_acronym":"NCT05472857","lead_sponsor":"Suzhou Immunofoco Biotechnology Co., Ltd","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMC002"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/08/2022","start_date":" 08/08/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"},{"id":"c23452ee-9413-4c76-bc52-df1b531d2d45","acronym":"","url":"https://clinicaltrials.gov/study/NCT04581473","created_at":"2021-03-09T09:00:08.732Z","updated_at":"2024-07-02T16:35:16.030Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection","source_id_and_acronym":"NCT04581473","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 expression • CLDN18.2 positive","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiTan (rivoceranib) • irinotecan • satricabtagene autoleucel (CT041)"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2038","study_completion_date":" 06/30/2038","last_update_posted":"2024-03-06"},{"id":"65ca8a5e-0989-42c5-b8b3-bca3de969e16","acronym":"","url":"https://clinicaltrials.gov/study/NCT05981235","created_at":"2023-08-08T14:08:32.113Z","updated_at":"2025-02-25T15:01:02.369Z","phase":"Phase 1","brief_title":"Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors","source_id_and_acronym":"NCT05981235","lead_sponsor":"Peking University","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD6422"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/14/2023","start_date":" 12/14/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2024-01-01"},{"id":"71a3a4f5-c99c-458e-aa62-fed7409bf1e8","acronym":"ELIMYN18.2","url":"https://clinicaltrials.gov/study/NCT04404595","created_at":"2021-03-09T08:59:58.909Z","updated_at":"2024-07-02T16:35:25.770Z","phase":"Phase 1/2","brief_title":"Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers","source_id_and_acronym":"NCT04404595 - ELIMYN18.2","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e satricabtagene autoleucel (CT041)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2023-12-19"},{"id":"c29522a3-7871-451f-9b15-79b2e1027e0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084286","created_at":"2023-10-16T15:12:50.114Z","updated_at":"2024-07-02T16:35:33.444Z","phase":"Phase 1","brief_title":"Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors","source_id_and_acronym":"NCT06084286","lead_sponsor":"Sichuan University","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 10/30/2026","primary_completion_date":" 10/30/2026","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2023-10-16"},{"id":"ce53abad-b3e8-4c4b-9177-ef32c0764dd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05946226","created_at":"2023-07-14T18:09:04.276Z","updated_at":"2024-07-02T16:35:35.396Z","phase":"Phase 1","brief_title":"A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors","source_id_and_acronym":"NCT05946226","lead_sponsor":"Suzhou Immunofoco Biotechnology Co., Ltd","biomarkers":" CLDN18 • IL6 • IL2 • IL10","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18 • IL6 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMC001 • IMC002 • danburstotug (IMC-001)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-28"},{"id":"7b029c78-c0f1-495b-b975-8a7772f7b283","acronym":"","url":"https://clinicaltrials.gov/study/NCT05952375","created_at":"2023-07-20T14:08:51.313Z","updated_at":"2024-07-02T16:35:42.572Z","phase":"","brief_title":"Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial","source_id_and_acronym":"NCT05952375","lead_sponsor":"The Affiliated Hospital of Qingdao University","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e XKDCT086"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2023-07-19"},{"id":"8b07e205-119f-4afe-8cd2-9116f0158ed2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05393986","created_at":"2022-05-27T12:55:36.060Z","updated_at":"2024-07-02T16:35:46.880Z","phase":"Phase 1","brief_title":"Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors","source_id_and_acronym":"NCT05393986","lead_sponsor":"Peking University","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CT048"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/04/2022","start_date":" 08/04/2022","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-05-31"},{"id":"ccc06936-f76a-49da-b8fa-d22d094886ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05199519","created_at":"2022-01-20T14:53:32.658Z","updated_at":"2024-07-02T16:35:47.265Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345","source_id_and_acronym":"NCT05199519","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IBI-345"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 10/29/2022","primary_completion_date":" 10/29/2022","study_txt":" Completion: 01/19/2023","study_completion_date":" 01/19/2023","last_update_posted":"2023-05-24"},{"id":"4e8933c7-95c5-47ee-93c6-8de36a6aa90b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05837299","created_at":"2023-05-01T14:04:02.008Z","updated_at":"2024-07-02T16:35:49.216Z","phase":"Phase 1","brief_title":"A Study of IMC008 for Advanced Solid Tumors","source_id_and_acronym":"NCT05837299","lead_sponsor":"Changhai Hospital","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMC008"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/02/2023","start_date":" 04/02/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2023-05-01"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"4ec6aa27-3db0-4988-ad1b-af35a4aa997e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05583201","created_at":"2022-10-17T13:56:08.698Z","updated_at":"2024-07-02T16:35:56.294Z","phase":"Phase 1","brief_title":"NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors","source_id_and_acronym":"NCT05583201","lead_sponsor":"jianming xu","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KD-496"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/13/2022","start_date":" 10/13/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-02-07"},{"id":"bd7f63a8-2425-45a1-92e6-30ab5aa123ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05620732","created_at":"2022-11-17T14:57:08.631Z","updated_at":"2024-07-02T16:36:00.091Z","phase":"","brief_title":"Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T","source_id_and_acronym":"NCT05620732","lead_sponsor":"Shenzhen University General Hospital","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2022-11-22"},{"id":"2ed8ac1b-05a8-4919-930c-9b6f1bb7320a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05277987","created_at":"2022-03-14T13:53:56.733Z","updated_at":"2024-07-02T16:36:15.503Z","phase":"Phase 1","brief_title":"An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects","source_id_and_acronym":"NCT05277987","lead_sponsor":"Shenzhen Fifth People's Hospital","biomarkers":" HER-2 • CLDN18","pipe":"","alterations":" ","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HEC-016"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2022-03-14"},{"id":"d64db104-1c14-4a1f-a553-5fd530a13586","acronym":"","url":"https://clinicaltrials.gov/study/NCT05275062","created_at":"2022-03-11T15:53:35.401Z","updated_at":"2024-07-02T16:36:15.601Z","phase":"Phase 1","brief_title":"Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT05275062","lead_sponsor":"Beijing Immunochina Medical Science \u0026 Technology Co., Ltd.","biomarkers":" CLDN18 • CA 19-9","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IM92"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/15/2022","start_date":" 02/15/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-03-11"},{"id":"4ba245b3-cdd7-41e7-a5f3-8109c12962b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04977193","created_at":"2021-07-26T17:53:30.495Z","updated_at":"2024-07-02T16:36:27.467Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma","source_id_and_acronym":"NCT04977193","lead_sponsor":"Shanghai Longyao Biotechnology Inc., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY011"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2021-07-26"},{"id":"e617ee9b-040b-4fd4-9b5a-793a47268767","acronym":"","url":"https://clinicaltrials.gov/study/NCT04966143","created_at":"2021-07-19T14:52:25.456Z","updated_at":"2024-07-02T16:36:27.788Z","phase":"Phase 1","brief_title":"Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer","source_id_and_acronym":"NCT04966143","lead_sponsor":"Shanghai Longyao Biotechnology Inc., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY011"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2021-07-19"},{"id":"9db49392-63c3-451c-aa4c-e6815cfac1d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03159819","created_at":"2021-01-19T14:12:33.040Z","updated_at":"2024-07-02T16:37:13.096Z","phase":"","brief_title":"Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT03159819","lead_sponsor":"Changhai Hospital","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e satricabtagene autoleucel (CT041)"],"overall_status":"Unknown status","enrollment":" Enrollment 24","initiation":"Initiation: 04/01/2017","start_date":" 04/01/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2018-03-12"}]